BioLineRx Ltd. (BLRX) Rating Reiterated by Roth Capital
BioLineRx Ltd. (NASDAQ:BLRX)‘s stock had its “buy” rating reissued by Roth Capital in a research report issued to clients and investors on Monday. They presently have a $7.00 target price on the stock.
A number of other research analysts have also recently issued reports on BLRX. Zacks Investment Research cut shares of BioLineRx from a “hold” rating to a “sell” rating in a report on Thursday, November 24th. Maxim Group set a $1.00 price objective on shares of BioLineRx and gave the stock a “hold” rating in a research note on Tuesday, November 22nd. Finally, S&P Equity Research dropped their price objective on shares of BioLineRx from $1.24 to $1.10 in a research note on Friday, September 23rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. BioLineRx has an average rating of “Hold” and a consensus target price of $2.68.
Shares of BioLineRx (NASDAQ:BLRX) opened at 1.01 on Monday. The firm has a 50-day moving average price of $0.00 and a 200-day moving average price of $0.00. The stock’s market cap is $57.00 million. BioLineRx has a 12 month low of $0.71 and a 12 month high of $1.63.
BioLineRx (NASDAQ:BLRX) last issued its earnings results on Tuesday, November 22nd. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.07) by $0.01. Equities analysts expect that BioLineRx will post ($0.28) EPS for the current fiscal year.
A number of hedge funds have recently made changes to their positions in the company. KCG Holdings Inc. raised its stake in shares of BioLineRx by 414.1% in the third quarter. KCG Holdings Inc. now owns 151,029 shares of the company’s stock worth $174,000 after buying an additional 121,650 shares during the period. Morgan Stanley raised its stake in shares of BioLineRx by 13.8% in the third quarter. Morgan Stanley now owns 551,122 shares of the company’s stock worth $634,000 after buying an additional 66,900 shares during the period. Finally, Senvest Management LLC raised its stake in shares of BioLineRx by 25.4% in the third quarter. Senvest Management LLC now owns 4,443,500 shares of the company’s stock worth $5,110,000 after buying an additional 900,200 shares during the period. Hedge funds and other institutional investors own 13.53% of the company’s stock.
BioLineRx Company Profile
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Stock Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related stocks with our FREE daily email newsletter.